CPT code 45381 – Colonoscopy with submucosal injection

Key takeaways

CPT 45381 covers colonoscopy with directed submucosal injection of any substance, including saline lifts, India ink tattoos, and hemostatic agents.

It is a standalone (not add-on) code. Report 45381 instead of 45378. Use Modifier 59 only when billing it with another therapeutic code such as 45380 or 45385.

Documentation must name the substance injected, the site, and the clinical indication, or claims will be denied on medical necessity grounds.

Pabau’s claims management software supports CPT and ICD-10 coding workflows to reduce denial rates for GI practices billing 45381.

CPT code 45381: Official description and procedure overview

CPT code 45381, as maintained by the American Medical Association (AMA), carries the official descriptor: “Colonoscopy, flexible; with directed submucosal injection(s), any substance.” It belongs to Category I of the CPT code set and is a standalone, non-add-on code. It replaces the diagnostic base code 45378 whenever a directed injection is the therapeutic act.

The word “directed” in the descriptor is clinically significant. It means the injection targets a specific site, not a diffuse or prophylactic application. A blanket mucosal rinse does not meet the threshold. The endoscopy report must identify the exact anatomical site where the injection was delivered.

What 45381 covers and what it excludes

Three clinical scenarios support billing CPT 45381. Outside these, the code does not apply even if a substance was introduced during the colonoscopy.

• Submucosal lift before removal: Saline, epinephrine-saline mix, hyaluronic acid, or a similar solution is injected beneath a polyp or lesion. It raises the lesion away from the muscularis propria before removal, and this is the most common indication.
• Tattooing for surgical localization: India ink injected submucosally to mark a lesion site for later surgical resection or surveillance. The tattoo is the directed injection.
• Hemostatic injection: Epinephrine or another hemostatic agent injected at a bleeding site during the colonoscopy to achieve hemostasis.

What 45381 does not cover is equally important. A snare polypectomy is CPT 45385, not 45381. A biopsy is CPT 45380, and a colonoscopy with no therapeutic intervention is 45378. An EMR reported as 45390 already includes the lift injection, so 45381 is not added for that lesion.

How 45381 differs from 45378, 45380 and 45385

The most frequent coding confusion in GI practices involves choosing between 45378, 45380, 45381, and 45385. Each has a distinct clinical trigger. Picking the wrong one results in either undercoding (lost revenue) or overcoding (audit risk).

A submucosal lift right before a snare polypectomy is the most common case where 45381 and 45385 meet. Bill both codes, check the current NCCI table for the pair, and leave 45378 off the claim. When the lift and the snare treat separate lesions or sites, append Modifier 59 to 45381.

Documentation requirements for a clean CPT 45381 claim

The endoscopy report is the billing record for CPT 45381. Every element below must appear in writing before the claim is submitted, or the payer has grounds for a medical necessity denial. Building a clean claim for 45381 starts with what the gastroenterologist documents in the procedure note.

• Substance injected: Name the agent specifically. “Saline,” “epinephrine-saline 1:10,000,” “India ink,” or the brand name of a viscous lifting agent. Vague language such as “solution” or “fluid” is not sufficient.
• Volume injected: Record the approximate volume at each site. Some payers require this to support medical necessity for the injection volume used.
• Anatomical site: Document the colonic segment where the injection was delivered, using standard GI nomenclature (cecum, ascending colon, hepatic flexure, and so on).
• Clinical indication: State the reason for the injection, such as “submucosal lift to facilitate removal of a 15mm flat lesion in the sigmoid colon.” Other examples are “India ink tattoo placed 2 cm distal to a 12mm sessile polyp” and “epinephrine injection for hemostasis at post-polypectomy site.”
• Extent of scope: Document that the colonoscopy reached the cecum (or explain withdrawal due to inadequate prep), consistent with a complete colonoscopy.
• Concurrent interventions: If a polypectomy or biopsy was also performed, document each separately so multiple codes are supported.

A superbill that captures the procedure details at the point of care should link to the full procedure note. That creates the documentation chain payers expect during a post-payment audit.

Modifiers for CPT 45381: When and how to use them

CPT 45381 needs a modifier when it is billed alongside another therapeutic colonoscopy code in the same session. The modifier tells the payer that two distinct services were performed, not one bundled procedure.

Medicare recognizes the X-modifiers as more specific alternatives to 59, and some contractors prefer them. Commercial payers generally accept Modifier 59. Check each payer’s current policy before billing, as guidance differs by contractor and plan.

NCCI edits and bundling rules affecting CPT 45381

The National Correct Coding Initiative (NCCI) sets column 1/column 2 edit pairs that control how 45381 can be billed alongside adjacent codes. CMS updates these edits quarterly, so check the current NCCI edit tables before billing any code combination.

• 45381 and 45378 (base colonoscopy): 45378 is the column 2 component of 45381, because the diagnostic exam is part of every therapeutic colonoscopy. Do not bill 45378 with it. A modifier unbundles the pair only when the two were separate encounters.
• 45381 and 45380 (biopsy): Billable together with Modifier 59 when the biopsy and the injection are at separate lesions or sites. A common case is a lesion biopsy plus an India ink tattoo placed a few centimeters away to mark it.
• 45381 and 45385 (snare polypectomy): Billable together with Modifier 59 when the two services treat separate lesions or sites. A lift before a snare polypectomy is a standard technique, so confirm the current edit before adding a modifier.

The matrix below puts each of these pairings on a single claim line. It also covers the EMR and Medicare screening cases explained elsewhere in this guide.

For facility billing, OPPS APC grouping applies to HOPDs, and the ASC payment system applies to ASCs. Neither uses the professional fee schedule. The facility payment may package the injection into the session’s primary procedure, so facility coders should verify current packaging rules separately from physician coding.

Medicare reimbursement rates for CPT 45381

Medicare pays for CPT 45381 under the Medicare Physician Fee Schedule (MPFS), with the rate varying by place of service. Pabau, the practice management platform we build, sends claims through Claim.MD, its US clearinghouse partner.

Whichever route you use, the place-of-service code sits at claim level and decides which fee schedule rate applies. Always verify rates with the current-year CMS Physician Fee Schedule lookup tool, as rates update every January 1.

The facility rate paid to the physician is lower than the non-facility rate because the practice expense component reflects that the facility bears overhead costs. After submitting, review the electronic remittance advice (ERA) to confirm the correct rate was applied and to spot reductions under Medicare’s multiple endoscopy rule.

Payer prior authorization and coverage requirements for CPT 45381

Prior authorization requirements for CPT 45381 vary by payer and by clinical indication. Medicare does not generally require prior authorization for diagnostic or therapeutic colonoscopy. Coverage is governed by Noridian Article A57342 (Billing and Coding: Diagnostic and Therapeutic Colonoscopy), which applies to Noridian jurisdictions. Check your own MAC’s article.

Medical billing compliance requirements for GI practices include checking that the clinical indication for the injection matches the payer’s coverage policy before the procedure.

• Medicare: No prior authorization is typically required for 45381. Noridian Article A57342 applies in Noridian jurisdictions, so check your own MAC’s article. The ICD-10 code must support medical necessity: Z12.11 for screening, or a symptom or diagnosis code such as K63.5 or K92.1.
• UnitedHealthcare (UHC): UHC publishes a Gastroenterology Endoscopy Advance Notification CPT Code List that includes colonoscopy codes. Check uhcprovider.com for the current crosswalk document and notification requirements for 45381 specifically.
• Aetna and BCBS plans: Requirements vary by plan and state. Therapeutic colonoscopy codes including 45381 may require notification or authorization when performed as a planned procedure rather than an urgent intraoperative finding.

The safest workflow is to verify coverage and authorization through the payer’s provider portal before scheduling any elective case with a planned submucosal injection.

Top reasons CPT 45381 claims are denied and how to fix them

Denials for CPT 45381 cluster around a predictable set of errors. The top preventable ones are billing 45378 with 45381, or omitting the modifier when 45381 pairs with 45380 or 45385.

When a payer returns one of these, the claim adjustment reason code on the remittance names the problem. Our guide to denial codes for billers decodes each one. A structured denial management process that tracks them by CPT code catches patterns quickly.

The claims management software within Pabau logs denial reasons against individual procedure codes. GI billing teams can then spot systematic issues instead of investigating each denial on its own.

Screening vs diagnostic colonoscopy: How it affects 45381 billing

Whether the colonoscopy began as a screening or a diagnostic encounter changes how Medicare processes a 45381 claim. When a screening turns therapeutic in the same session, the claim keeps Z12.11 as the first-listed diagnosis and adds a PT modifier.

• Screening converted to therapeutic: When a Medicare screening colonoscopy (G0105 for high-risk or G0121 for average-risk patients) includes a submucosal injection, the patient owes coinsurance. Medicare coinsurance on a screening that becomes therapeutic is 15% through 2026, falling to 10% in 2027-2029 and 0% from 2030.
• Diagnosis code selection: When screening is the encounter’s primary purpose, Z12.11 (encounter for screening for malignant neoplasm of colon) drives the claim. When symptoms prompted the colonoscopy, use the relevant symptom or diagnosis code (K63.5, K92.1, K57.xx, or C18.x as appropriate). The diagnosis code must align with the clinical rationale for the injection.
• G-code vs CPT code: Bill 45381 with Modifier PT and Z12.11 as the first-listed diagnosis. Do not bill G0105/G0121 as well. Confirm your Medicare contractor’s current guidance, as screening rules are updated with each annual MPFS release.

ICD-10 diagnosis codes commonly paired with CPT 45381

The diagnosis code submitted with CPT 45381 must logically support the need for a directed submucosal injection. The AAPC code lookup and Noridian Article A57342 both address which diagnosis categories establish medical necessity for therapeutic colonoscopy. A57342 applies to Noridian jurisdictions, so check your own MAC’s article.

Payer LCD policies and billing articles define which diagnosis codes are covered for each procedure code. Verify the applicable policy for your Medicare Administrative Contractor before billing, since covered diagnoses for 45381 may vary between jurisdictions.

How Pabau’s claims management cuts 45381 denials

Today, a GI biller usually finds a 45381 problem after the fact. The remittance arrives with a denial code, and someone traces it back by hand. The cause is often a note that never named the substance, or a claim that still carried 45378.

Pabau keeps the procedure note, the codes and the claim on the same patient record. Modifiers are attached before submission, and claims route through Claim.MD with the place-of-service code already set.

Denial reasons are logged against each procedure code, so a run of 45378 pairing errors or missing modifiers shows up as a pattern. Your billing team fixes the report template once instead of appealing claim by claim.

Reduce GI billing denials with Pabau

Pabau’s claims management workflows help GI practices track CPT codes, apply correct modifiers, and submit clean 45381 claims across professional and facility settings.

Book a demo

Conclusion

CPT 45381 rewards practices that settle the claim line before the scope is withdrawn. The most preventable denials are billing 45378 with 45381, or omitting the modifier when 45381 pairs with 45380 or 45385. Missing substance documentation is the third.

Put a substance field and an injection-site field in the endoscopy report template, and check screening status before the claim is built. The trade-off is a slightly longer procedure note, which costs far less than one appeal.

Book a demo to see how Pabau links GI procedure notes to clean 45381 claims.

Continue your research

Weighing up the biopsy code that pairs with 45381? CPT code 45380 covers colonoscopy with biopsy, including when it bills alongside an injection.

Need the diagnostic base code 45381 replaces? CPT code 45378 explains the diagnostic colonoscopy and why it drops off a therapeutic claim.

Billing an average-risk Medicare screening? HCPCS code G0121 covers the screening code and what changes when the scope turns therapeutic.

Looking to understand denial reason codes on your EOBs? Denial codes in medical billing explains CARC and RARC codes so GI billing teams can act on remittance advice faster.

Need a structured overview of clearinghouse submission for colonoscopy claims? Medical claims clearinghouse guide covers how 837P files route from practice to payer and how rejections differ from denials.

Frequently asked questions